使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning, ladies and gentlemen, and welcome to Baxter International's Fourth Quarter 2018 Earnings Conference Call. (Operator Instructions)
各位女士、先生,早安,歡迎參加百特國際(Baxter International)2018 年第四季財報電話會議。(接線員指示)
As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.
提醒各位,本次電話會議由百特錄音,並受著作權保護。未經百特許可,不得錄音或轉播。如您有任何異議,請立即掛線。
I would now like to turn the call over to Ms. Clare Trachtman, Vice President, Investor Relations at Baxter International. Ms. Trachtman, you may begin.
現在我想把電話交給百特國際投資人關係副總裁 Clare Trachtman 女士。Trachtman 女士,請開始。
Clare Trachtman - VP of IR
Clare Trachtman - VP of IR
Thanks, Candace.
謝謝你,Candace。
Good morning, and welcome to our fourth quarter 2018 earnings conference call. Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; and Jay Saccaro, Baxter's Chief Financial Officer.
早安,歡迎參加我們 2018 年第四季財報電話會議。今天與我一同出席的有百特董事長兼執行長 Joe Almeida,以及百特財務長 Jay Saccaro。
On the call this morning, we will be discussing Baxter's fourth quarter and full year 2018 financial results along with our financial outlook for 2019. A supplemental presentation to complement this morning's discussion can be accessed on our website. This presentation, along with related non-GAAP reconciliations, can also be accessed on Baxter's external website in the Investors section under Events and News.
今天上午的電話會議中,我們將討論百特 2018 年第四季與全年財務結果,以及我們對 2019 年的財務展望。可至我們的網站取得補充簡報,以配合今天上午的討論。此簡報及相關的非 GAAP 調節表,也可在百特對外網站「投資人」專區的「活動與新聞」項下取得。
With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook, new product development, business development and regulatory matters, contain forward-looking statements that involve risks and uncertainties. And of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more details concerning factors that could cause actual results to differ materially.
在開始我們的預備發言前,先提醒各位,本簡報(包括關於我們財務展望、新產品開發、業務開發及法規事項的評論)包含前瞻性陳述,涉及風險與不確定性。當然,我們的實際結果可能與目前預期有重大差異。有關可能導致實際結果與預期有重大差異的因素,請參閱今日新聞稿及我們向美國證券交易委員會(SEC)提交的文件,以取得更多資訊。
In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website.
此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續營運的業務表現。今日所討論之非 GAAP 財務衡量指標與可比 GAAP 財務衡量指標的調節表,已包含於我們今早發布的財報新聞稿中,並可在我們網站上取得。
On the call this morning, we will be discussing operational sales growth, which, for historical periods, adjusts for the impact of foreign exchange, generic competition for U.S. cyclophosphamide, our acquisition of 2 surgical products from Mallinckrodt in the first quarter of 2018 and, for full year 2019, approximately 7 months of sales from the acquisition of Claris in July 2017. 2019 operational sales growth guidance adjusts for the impact of foreign exchange and generic competition for U.S. cyclophosphamide.
今天上午的電話會議中,我們將討論營運銷售成長;就歷史期間而言,該指標已調整外匯影響、美國 cyclophosphamide 的學名藥競爭、我們於 2018 年第一季自 Mallinckrodt 收購 2 項外科產品的影響,以及就 2019 全年而言,包含 2017 年 7 月收購 Claris 後約 7 個月的銷售額。2019 年營運銷售成長指引已調整外匯影響及美國 cyclophosphamide 的學名藥競爭影響。
Now I'd like to turn the call over to Joe. Joe?
現在我想把電話交給 Joe。Joe?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Good morning, and thank you for joining us. We are pleased to share our fourth quarter results with you today and to discuss our expectations for 2019. I will begin with a quick review of our fourth quarter performance before sharing my reflections on the year as a whole. Jay will then provide more detail on the financials, including our 2019 outlook. We will wrap up with Q&A.
早安,感謝各位加入我們。我們很高興今天與各位分享第四季業績,並討論我們對 2019 年的預期。我將先快速回顧第四季表現,再分享我對全年表現的看法。接著 Jay 將提供更詳細的財務說明,包括我們對 2019 年的展望。最後我們將進行問答。
Baxter closed the year with a solid fourth quarter, delivering sales growth of 2% on a reported basis and 5% on both a constant currency and operational basis. A strategic execution, a strong operational performance and disciplined financial management resulted in adjusted EPS of $0.78, up 22% year-over-year. Drivers of growth in the quarter included the company's Renal Care, Pharmaceuticals, Advanced Surgery and Acute Therapies businesses. Increased demand for Baxter's contract manufacturing services also contributed to performance in the quarter. This strength helped offset performance in our Medication Delivery and Nutrition businesses, which was in line with the guidance we shared on our third quarter call.
百特以穩健的第四季為 2018 年畫下句點:以申報基礎計,銷售成長 2%;以固定匯率及營運基礎計,銷售皆成長 5%。策略執行到位、強勁的營運表現與嚴謹的財務管理,使調整後每股盈餘(adjusted EPS)達 0.78 美元,年增 22%。本季成長動能來自公司腎臟照護、製藥、先進外科與急性療法等業務。百特合約製造服務需求增加亦對本季表現有所貢獻。這些強勁表現有助於抵銷我們藥物輸注(Medication Delivery)與營養(Nutrition)業務的表現,而該表現與我們在第三季電話會議中提供的指引一致。
Growth in Renal Care continues to benefit from increased demand for our peritoneal dialysis products globally. In the U.S., we experienced the highest growth for PD patients of the year with patient volumes increasing high single digits in the fourth quarter. And in Japan, the successful rollout of KAGUYA is also contributing to performance with patient growth advancing mid-single digits in the quarter.
腎臟照護的成長持續受惠於全球對我們腹膜透析(PD)產品需求增加。在美國,我們在第四季出現全年最高的 PD 病患成長,病患量以高個位數百分比增加。在日本,KAGUYA 的成功推廣也帶動表現,本季病患成長提升至中個位數百分比。
In Pharmaceuticals, growth in the quarter was driven by strength across the portfolio globally. Increased sales of premixed injectables, anesthesia and critical care products as well as a strong performance in our pharmacy compounding business all contributed to growth. This helped to offset expected lower U.S. sales of BREVIBLOC and cyclophosphamide in the quarter.
在製藥業務方面,本季成長由全球產品組合的全面強勁表現所帶動。預混注射劑、麻醉與重症照護產品銷售增加,以及我們藥局調劑(pharmacy compounding)業務的強勁表現,皆對成長有所貢獻。這有助於抵銷本季美國 BREVIBLOC 與 cyclophosphamide 銷售如預期下滑的影響。
Advanced Surgery achieved growth of 17% on a constant currency basis in the quarter, including a contribution of approximately $20 million from sales of RECOTHROM, which benefit from competitive supply constraints during the quarter.
先進外科業務本季以固定匯率計成長 17%,其中約 2,000 萬美元來自 RECOTHROM 的銷售貢獻,受惠於本季競品供應受限。
Performance in Acute Therapies continue to be driven by improving utilization for CRRT globally as well as increased demand for our multi-organ support products.
急性療法業務的表現持續由全球 CRRT 使用率提升,以及對我們多器官支持產品需求增加所帶動。
Finally, performance in our U.S. Medication Delivery and Nutrition businesses has stabilized, and we are in the process of executing on efforts to return demand for impacted products to pre-hurricane levels. In addition, we are seeing closer alignment between end user unit demand and financial unit purchases for large-volume IV solutions.
最後,我們在美國的藥物輸注與營養業務表現已趨於穩定,我們正執行相關措施,將受影響產品的需求恢復至颶風前水準。此外,我們也看到大容量靜脈輸液(large-volume IV solutions)的終端使用者單位需求與財務單位採購之間的差距更為收斂。
As we discussed last quarter, going forward, we continue to expect these businesses to grow in line with their respective market growth rates as well as benefit from new product launches. In addition, last quarter, I mentioned that we were taking decisive action to renew strategic momentum in our U.S. hospital businesses. To this end, I'm pleased to announce that Heather Knight will join us as the new General Manager for our U.S. hospital business effective February 11. I worked with Heather previously, so I know firsthand that she will bring outstanding leadership skills and superior insights on the medical device market.
如同我們上季所討論的,展望未來,我們仍預期這些業務將與各自市場成長率一致成長,並受惠於新產品上市。此外,上季我提到,我們正採取果斷行動,以重振我們美國醫院業務的策略動能。為此,我很高興宣布 Heather Knight 將於 2 月 11 日起加入我們,擔任美國醫院業務的新任總經理。我過去曾與 Heather 共事,因此我親身了解她將帶來卓越的領導能力,以及對醫療器材市場的深刻洞見。
On our fourth quarter performance, it illustrates important progress in our long-term strategic journey. Baxter's emphasis on increasing innovation, unwavering financial discipline and driving operational efficiency all contributed to our ongoing growth.
就我們第四季的表現而言,這展現了我們在長期策略旅程中的重要進展。百特著重提升創新、堅守財務紀律並推動營運效率,皆促成我們持續成長。
For the full year 2018, Baxter achieved sales growth of 5% on a reported basis, 4% on a constant currency basis and 3% on an operational basis. Our overall strength was also reflected geographical, where we achieved mid-single-digit constant currency sales growth across all 3 of our geographic reporting segments: Americas, APAC and EMEA. Of note, Q4 represented the highest quarterly operational growth of the year for both our APAC and EMEA regions.
2018 全年,百特以申報基礎計銷售成長 5%,以固定匯率計成長 4%,以營運基礎計成長 3%。我們的整體強勁表現也反映在各地區:在三個地理報告分部——美洲、亞太(APAC)與歐洲、中東及非洲(EMEA)——皆達成以固定匯率計的中個位數百分比銷售成長。值得一提的是,第四季是我們 APAC 與 EMEA 兩個地區全年營運成長最高的季度。
Our momentum carried over to the bottom line. Our adjusted EPS was $3.05, up 23% year-over-year. And Baxter generated free cash flow of over $1.4 billion in 2018, up 16% versus 2017.
我們的成長動能延續到最終獲利表現。我們的調整後每股盈餘(EPS)為 3.05 美元,年增 23%。此外,Baxter 於 2018 年創造超過 14 億美元的自由現金流,較 2017 年成長 16%。
Creating value for stockholders is essential for our business model. In 2018, we increased our quarterly dividend by 19% and returned over $2.4 billion to investors through our share repurchase program. In addition, the research and development and commercial milestones we achieved in 2018 and the early weeks of 2019 demonstrate a promising future of organic growth through innovation. Earlier this month, we announced that we had enrolled the first patients in our U.S. clinical trial for our in-home, on-demand PD solution generation system. Now a few weeks later, patient treatments are under way. We believe that this technology has great potential to improve the patient experience and simplify therapy management.
為股東創造價值是我們商業模式的核心。2018 年,我們將季度股利提高 19%,並透過股票回購計畫向投資人返還超過 24 億美元。此外,我們在 2018 年以及 2019 年初幾週達成的研發與商業里程碑,展現了透過創新帶動有機成長的可期前景。本月稍早,我們宣布已在美國針對居家、按需 PD 解決方案生成系統的臨床試驗中納入首批病患。而在幾週後的現在,病患治療已在進行中。我們相信這項技術具有極大潛力,可改善病患體驗並簡化治療管理。
In 2018, we announced a collaboration with the Mayo Clinic to establish a renal care center of excellence, serving patients across a continuum of care to drive improved outcomes. This will be an opportunity to put our combined expertise to work in new ways. It also represents a meaningful pathway for pursuing other creative collaborations with the potential to advance patient care and drive business performance.
2018 年,我們宣布與梅奧診所(Mayo Clinic)合作,建立腎臟照護卓越中心,服務涵蓋照護全流程的病患,以推動更佳的治療結果。這將是讓我們結合的專業能力以新方式發揮作用的機會。這也代表一條具意義的途徑,可進一步尋求其他具創意的合作,有望推進病患照護並帶動業務表現。
And 2018 also featured a range of pivotal, differentiated new product launches from across all 6 of our businesses. Our leading-edge PrisMax, CRRT and organ support technology is now helping treat acute care patients in multiple European markets. As I mentioned earlier, the KAGUYA APD cycler with embedded Sharesource technology is quickly being embraced in Japan and is a compelling in-home therapy option. Our Spectrum IQ smart pump platform is now being adopted in the U.S. and Canada, and the Evo IQ pump platform is being launched in other global markets. Additional launches across the U.S. and around the world include IV pharmaceuticals, surgical hemostats and sealants and nutritionals.
而 2018 年也見證了我們 6 大事業群推出一系列關鍵且具差異化的新產品。我們領先業界的 PrisMax、CRRT 與器官支持技術,現已在多個歐洲市場協助治療急重症病患。如我先前提到的,內建 Sharesource 技術的 KAGUYA APD 透析機在日本迅速獲得採用,並成為具吸引力的居家治療選項。我們的 Spectrum IQ 智慧輸注幫浦平台目前正於美國與加拿大導入,而 Evo IQ 幫浦平台也正於其他全球市場推出。在美國及全球各地的其他上市產品還包括靜脈注射(IV)藥品、外科止血劑與封合劑,以及營養產品。
As 2019 unfolds, we're moving ahead at full speed. We're continuing to address unmet patient and customer needs, building out our pipeline and working with regulatory agencies to successfully launch our products across the globe. We continue to thoroughly assess opportunities to further our impact to patients and health care providers through strategic partnerships and business development. And we remain intently focused on expanding efficiencies across the organization. This all support our objective to accelerate performance and deliver top-quartile results for all the stakeholders.
隨著 2019 年展開,我們正全速前進。我們持續回應尚未被滿足的病患與客戶需求,擴充產品管線,並與監管機構合作,以在全球成功推出我們的產品。我們也持續全面評估機會,透過策略夥伴關係與業務發展,進一步擴大我們對病患與醫療照護提供者的影響力。同時,我們仍高度專注於在整個組織中擴大效率提升。以上皆支持我們加速績效表現、為所有利害關係人交出同業前四分位的成果之目標。
Now I will pass it to Jay, who will walk you through the financials in more detail.
接下來我將交給 Jay,由他帶各位更深入了解財務表現。
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Thanks, Joe, and good morning, everyone.
謝謝你,Joe,各位早安。
As Joe mentioned, our fourth quarter results demonstrate a strong finish to 2018. Throughout the year, we delivered consistent bottom line strength through improved operational performance, coupled with the ongoing benefit of our business transformation initiatives. Moving into 2019 and beyond, we continue to be well positioned to achieve our long-term financial goals.
如 Joe 所提到的,我們第四季的結果展現了 2018 年強勁的收官。全年而言,我們透過營運表現改善,並結合業務轉型計畫持續帶來的效益,交出穩健一致的獲利表現。展望 2019 年及更長期,我們仍處於有利位置,可達成長期財務目標。
I'll start by discussing our fourth quarter and full year 2018 results before providing our financial outlook for 2019.
我將先說明第四季與 2018 全年的業績,接著提供 2019 年的財務展望。
Beginning with the fourth quarter, global sales of $2.8 billion increased 2% on a reported basis and 5% on both a constant currency and operational basis. This was favorable to our expectations, driven by performance in our Renal Care, Pharmaceuticals and Advanced Surgery businesses.
先從第四季開始,全球銷售額 28 億美元,以報告基礎成長 2%,以固定匯率與營運基礎皆成長 5%。此表現優於我們的預期,主要由腎臟照護、藥品與先進外科事業的表現所帶動。
On the bottom line, adjusted earnings increased 22% to $0.78 per diluted share. This also exceeded our previous guidance of $0.71 to $0.73 per share, driven primarily by sales performance, disciplined financial management and a modest benefit from increased share repurchase activity, which Joe referenced earlier.
在獲利方面,調整後盈餘成長 22%,至稀釋後每股 0.78 美元。這也超過我們先前每股 0.71 至 0.73 美元的指引,主要受惠於銷售表現、嚴謹的財務管理,以及 Joe 先前提到的、因增加股票回購活動而帶來的小幅助益。
Now I'll walk you through performance by our geographic segments and Global Business Units. Note, for this quarter, constant currency sales growth is equal to operational sales growth for all businesses with the exceptions of our Pharmaceuticals and Advanced Surgery businesses and for the Americas region for which we will provide operational growth in addition to constant currency growth.
接下來我將說明各地理區隔與全球事業單位(Global Business Units)的表現。請注意,本季除藥品與先進外科事業,以及美洲地區之外,各事業的固定匯率銷售成長等同於營運銷售成長;對於上述例外,我們將在提供固定匯率成長之外,另行提供營運成長。
Starting first with sales growth for our 3 geographic segments.
首先從三大地理區隔的銷售成長談起。
Sales in the Americas advanced 4% on a constant currency basis and 3% operationally. Sales in both our EMEA and APAC regions advanced 6% on a constant currency basis.
美洲地區銷售以固定匯率計成長 4%,以營運基礎計成長 3%。EMEA 與 APAC 兩個地區的銷售以固定匯率計皆成長 6%。
Moving on to performance by Global Business Units.
接著看各全球事業單位的表現。
Global sales for Renal Care were $953 million, advancing 5% on a constant currency basis. As Joe mentioned, performance in the quarter was driven by high single-digit growth for PD therapies globally. Partially offsetting this growth was lower U.S. sales of in-center HD primarily related to lower sales of low-margin distributed bloodlines.
腎臟照護的全球銷售額為 9.53 億美元,以固定匯率計成長 5%。如 Joe 所提到,本季表現主要由全球 PD 治療的高個位數成長所帶動。部分抵銷此成長的是美國院內 HD 銷售下滑,主要與低毛利的經銷血路管(distributed bloodlines)銷售下降有關。
Sales in Medication Delivery of $660 million were flat on a constant currency basis, in line with the expectations we communicated last quarter. During the quarter, we continued to work with distributors as they reduced their inventory levels. We believe the destocking is largely complete, and distributor purchases will now more closely align with end user demand.
藥物輸送(Medication Delivery)銷售額為 6.60 億美元,以固定匯率計持平,符合我們上季所溝通的預期。本季期間,我們持續與經銷商合作,因其正在降低庫存水位。我們認為去庫存大致已完成,經銷商的採購將更貼近終端使用者需求。
With respect to small-volume parenterals, we are on track with our efforts to return demand to pre-hurricane levels as we continue to reinforce to our customers the safety and efficiency of our SVPs for drug reconstitution.
就小容量注射劑(SVP)而言,我們正按計畫推進,致力於在持續向客戶強化我們 SVP 於藥品重溶方面的安全性與效率之同時,使需求回到颶風前的水準。
Finally, pump sales came in slightly below expectations. As discussed last quarter, we're seeing a longer sales cycle for Spectrum IQ given the 2-way hospital connectivity with the hospital EMR as well as customers somewhat delaying purchases of new pumps. Despite these dynamics, we gained just under 1 point of market share in 2018 and expect to gain a similar amount in 2019.
最後,幫浦銷售略低於預期。如上季所討論,鑑於 Spectrum IQ 與醫院電子病歷(EMR)的雙向院內連線需求,以及部分客戶稍微延後採購新幫浦,我們看到較長的銷售週期。儘管有這些動態,我們在 2018 年的市占率提升了略低於 1 個百分點,並預期 2019 年可取得相近幅度的提升。
Pharmaceutical sales were $540 million, increasing 9% constant currency and 11% operationally. Growth in the quarter benefited from strength in our anesthesia and critical care products, driven by increased sales of Transderm Scop and sevoflurane. Strong sales of Baxter's injectable premixed drugs also contributed to growth in the quarter, benefiting from recent product launches. And finally, increased demand for Baxter's pharmaceutical -- pharmacy compounding services also contributed to performance. This growth was partially offset by lower sales of BREVIBLOC and cyclo during the quarter. U.S. cyclo and BREVIBLOC sales were $39 million and $14 million, respectively, in the quarter.
藥品(Pharmaceuticals)銷售額為 5.40 億美元,以固定匯率計成長 9%,以營運基礎計成長 11%。本季成長受惠於麻醉與重症照護產品的強勁表現,主要由 Transderm Scop 與 sevoflurane 的銷售增加所帶動。Baxter 的注射用預混藥品亦有強勁銷售,受惠於近期產品上市,並對本季成長有所貢獻。最後,對 Baxter 藥品——藥局調配服務(pharmacy compounding services)的需求增加,也帶動了表現。上述成長部分被本季 BREVIBLOC 與 cyclo 銷售下滑所抵銷。本季美國 cyclo 與 BREVIBLOC 的銷售額分別為 3,900 萬美元與 1,400 萬美元。
Moving to Nutrition, total sales were $215 million, down 5% on a constant currency basis. We continue to focus on driving growth recovery through market education and reinforcement of supply availability. During the quarter, we saw a slight pickup in the market, and our efforts to regain demand lost as a result of the hurricane are on track.
接著談到營養業務,總銷售額為2.15億美元,以固定匯率計下降5%。我們持續透過市場教育並強化供應可得性,專注於推動成長復甦。本季我們看到市場略有回溫,而我們為了收復因颶風而流失的需求所做的努力也按計畫推進。
Sales in Advanced Surgery were $214 million, increasing 17% constant currency and 5% operationally. Sales of RECOTHROM and PREVELEAK contributed approximately $21 million in the quarter. As Joe mentioned, RECOTHROM fourth quarter sales benefited from a competitor's supply constraints. These issues have since been resolved.
先進外科(Advanced Surgery)銷售額為2.14億美元,以固定匯率計成長17%,以營運基礎計成長5%。RECOTHROM與PREVELEAK本季合計貢獻約2,100萬美元的銷售額。如Joe所提,RECOTHROM第四季銷售受惠於競品供應受限。這些問題目前已解決。
Sales in our Acute Therapies business were $137 million, representing growth of 12% on a constant currency basis. Strong performance in the business continues to be driven by increased global demand for Baxter's continuous renal replacement therapies.
我們急性治療(Acute Therapies)業務銷售額為1.37億美元,以固定匯率計成長12%。該業務的強勁表現持續由全球對Baxter連續性腎臟替代治療(CRRT)需求增加所帶動。
Finally, sales in our other category, which primarily includes our contracting manufacturing services (sic) [contract manufacturing services] were $122 million, an increase of 14% on a constant currency basis. Performance in the quarter was driven by increased demand for our contract manufacturing services.
最後,我們的其他類別(主要包含我們的委託製造服務(原文誤稱)[contract manufacturing services])銷售額為1.22億美元,以固定匯率計成長14%。本季表現主要由委託製造服務需求增加所帶動。
Moving through the rest of the P&L. Our adjusted gross margin of 44.3% decreased 10 basis points over the prior year as the benefit of operational improvements were offset by certain onetime manufacturing costs in the quarter. Adjusted SG&A totaled $597 million, decreasing 4% on a reported basis and 2% on a constant currency basis, driven by our business transformation initiatives targeted with improving operational efficiency, which helped to offset the loss of approximately $9 million in transition service income received from Shire in 2017.
接著看損益表其餘項目。我們的調整後毛利率為44.3%,較去年下降10個基點;營運改善帶來的效益被本季某些一次性製造成本所抵銷。調整後銷售、一般及行政費用(SG&A)合計5.97億美元,以報告基礎計下降4%,以固定匯率計下降2%;主要受惠於我們以提升營運效率為目標的業務轉型計畫,並有助於抵銷2017年自Shire取得約900萬美元過渡服務收入的流失。
Adjusted R&D spending in the quarter of $165 million decreased 9% on a reported basis and 7% on a constant currency basis versus the prior year as we anniversaried certain milestone and third-party payments made in the fourth quarter of 2017. Strategic investment in our innovation pipeline continues to be a priority.
本季調整後研發支出為1.65億美元,以報告基礎計下降9%,以固定匯率計下降7%,主要因2017年第四季支付的部分里程碑與第三方款項在本季已屆滿比較基期。對我們創新產品管線的策略性投資仍是優先事項。
Adjusted operating margin in the quarter was 17.5%, an increase of 210 basis points versus the prior year. Growth was largely driven by operational expansion and continued focus on transforming how we more effectively manage our business.
本季調整後營業利益率為17.5%,較去年增加210個基點。成長主要由營運槓桿擴張,以及我們持續聚焦於轉型、以更有效方式管理業務所帶動。
Net interest expense was $11 million in the fourth quarter, and adjusted other income totaled $34 million in the quarter, primarily reflecting a benefit from changes in our U.S. pension plan and foreign exchange gains on balance sheet positions.
第四季淨利息費用為1,100萬美元,本季調整後其他收益合計3,400萬美元,主要反映美國退休金計畫變動帶來的利益,以及資產負債表部位的外匯收益。
The adjusted tax rate was 18.9% for the quarter. And as previously mentioned, adjusted earnings of $0.78 per diluted share exceeded our guidance of $0.71 to $0.73 per share.
本季調整後有效稅率為18.9%。如先前所述,調整後每股稀釋盈餘為0.78美元,高於我們每股0.71至0.73美元的指引。
Within the fourth quarter, we repurchased approximately $1.4 billion or 20.9 million shares of Baxter stock, reflecting our stated intention to strategically repurchase shares trading at a discount to our intrinsic value calculation.
在第四季期間,我們回購約14億美元、或2,090萬股Baxter股票,反映我們既定意圖:策略性回購相較於我們內在價值估算折價交易的股份。
Turning to full year 2018. Sales of $11.1 billion increased by 5% on a reported basis, 4% at constant currency and 3% on an operational basis. On the bottom line, adjusted earnings increased 23% to $3.05 per diluted share.
接著看2018年全年。銷售額111億美元,以報告基礎計成長5%,以固定匯率計成長4%,以營運基礎計成長3%。在獲利方面,調整後盈餘成長23%,至每股稀釋盈餘3.05美元。
On a full year basis, we generated free cash flow of more than $1.4 billion, marking an improvement of approximately $200 million or 16% versus the prior year. This is slightly below our guidance of approximately $1.5 billion primarily due to a higher year-ending inventory balance than we expected.
以全年計,我們創造超過14億美元的自由現金流,較去年改善約2億美元或16%。此數字略低於我們約15億美元的指引,主要因期末存貨餘額高於預期。
Let me conclude my comments this morning by providing our guidance for the first quarter and full year 2019.
最後,讓我以提供2019年第一季與全年指引來結束今天上午的說明。
For full year 2019, we expect flat to 1% reported sales growth globally, 2% to 3% constant currency and 3% to 4% operational. I would like to point out the key assumptions reflected in our full year sales outlook, which include approximately 200 basis points of foreign exchange impact and full year U.S. cyclophosphamide sales of approximately $95 million versus $166 million in 2018. Operational sales growth adjusts for the impact of foreign exchange and generic competition for U.S. cyclophosphamide in 2019. Operational growth includes the impact of approximately $75 million related to lower U.S. sales of BREVIBLOC as well as approximately $55 million of lower U.S. in-center HD sales. Collectively, these 2 factors negatively impact 2019 growth by approximately 130 basis points.
就2019年全年而言,我們預期全球報告銷售成長持平至1%,以固定匯率計成長2%至3%,以營運基礎計成長3%至4%。我想指出,全年銷售展望的關鍵假設包括:約200個基點的外匯影響,以及美國環磷醯胺(cyclophosphamide)全年銷售約9,500萬美元(2018年為1.66億美元)。營運銷售成長已調整外匯影響,以及2019年美國環磷醯胺面臨學名藥競爭的影響。營運成長亦包含約7,500萬美元的影響(與美國BREVIBLOC銷售降低相關),以及約5,500萬美元的影響(與美國院內血液透析(in-center HD)銷售降低相關)。合計而言,這兩項因素對2019年成長造成約130個基點的負面影響。
Moving to guidance by business. On a constant currency basis, except where otherwise noted, in Renal Care, we expect growth of 2% to 3%, reflecting continued momentum in PD, partially offset by lower sales of U.S. in-center HD, aligned with our stated strategy of enhancing performance by exiting lower-margin product lines.
接著按業務別說明指引。以固定匯率計(除非另有說明),在腎臟照護(Renal Care)方面,我們預期成長2%至3%,反映腹膜透析(PD)動能持續;部分被美國院內血液透析(in-center HD)銷售下降所抵銷,這也符合我們既定策略:退出較低毛利產品線以提升績效。
In Medication Delivery, we expect sales to increase approximately 6%.
在藥物輸送(Medication Delivery)方面,我們預期銷售約成長6%。
We expect our Pharmaceuticals business to decline 3% to 4% on a constant currency basis. Adjusting for U.S. cyclo, operational growth is expected to be flat to 2018, reflecting the lower BREVIBLOC sales I just mentioned.
我們預期製藥(Pharmaceuticals)業務以固定匯率計將下滑3%至4%。若調整美國環磷醯胺(U.S. cyclo)的影響,營運成長預期與2018年持平,反映我剛提到的BREVIBLOC銷售降低。
Moving to Clinical Nutrition. We expect sales growth of approximately 3% as we work to return customers in the U.S. back to pre-hurricane prescribing patterns.
接著看臨床營養(Clinical Nutrition)。我們預期銷售約成長3%,同時致力於讓美國客戶的處方模式回到颶風前的水準。
For our Advanced Surgery business, we expect sales to increase 3% to 4% on a constant currency basis.
在先進外科(Advanced Surgery)業務方面,我們預期以固定匯率計銷售成長3%至4%。
For the Acute Therapies business, we expect growth of approximately 7% to 8%.
在急性治療(Acute Therapies)業務方面,我們預期成長約7%至8%。
Finally, in our other business, we expect sales to decline low single digits as we don't currently anticipate the outperformance in 2018 to repeat in 2019.
最後,在其他業務方面,我們預期銷售將小幅下滑(低個位數),因為我們目前不預期2018年的超預期表現會在2019年重現。
Moving down the P&L. We anticipate adjusted operating margin expansion of 60 to 100 basis points. We expect net interest expense of approximately $60 million to $65 million and adjusted other income of approximately $80 million to $85 million for 2019.
接著往下看損益表。我們預期調整後營業利益率將擴張60至100個基點。我們預期2019年淨利息費用約6,000萬至6,500萬美元,調整後其他收益約8,000萬至8,500萬美元。
For the year, we expect an average adjusted tax rate of approximately 18% and a full year diluted average share count between the range of 515 million to 520 million shares.
全年而言,我們預期平均調整後有效稅率約18%,全年稀釋後平均股數介於5.15億至5.20億股。
Based on these factors, we expect 2019 adjusted earnings, excluding special items, of $3.22 to $3.30 per diluted share.
綜合上述因素,我們預期2019年調整後盈餘(不含特殊項目)為每股稀釋盈餘3.22至3.30美元。
And finally for the year, we expect to generate operating cash flow of approximately $2.3 billion and free cash flow of approximately $1.6 billion.
最後,就全年而言,我們預期將產生約23億美元的營運現金流,以及約16億美元的自由現金流。
Specific to the first quarter of 2019, we expect sales to decline approximately 3% on a reported basis, growth of approximately 1% on a constant currency basis and growth of 1% to 2% on an operational basis. And we expect adjusted earnings, excluding special items, of $0.66 to $0.68 per diluted share.
就2019年第一季而言,我們預期以申報口徑計算的銷售額將下滑約3%,以固定匯率口徑計算約成長1%,以營運口徑計算成長1%至2%。此外,我們預期調整後盈餘(不含特殊項目)為每股稀釋後0.66至0.68美元。
With that, we can now open up the call for Q&A.
接下來,我們現在可以開放電話會議進行問答。
Operator
Operator
(Operator Instructions) And our first question comes from David Lewis of Morgan Stanley.
(接線員指示) 我們的第一個問題來自摩根士丹利(Morgan Stanley)的David Lewis。
Jonathan Lee Demchick - Equity Analyst
Jonathan Lee Demchick - Equity Analyst
This is actually Jon Demchick on for David. Would love to kind of dive a little bit into the IV solutions part of the medical device or -- oh, the Medication Delivery business and kind of think about what projections you're expecting for the first couple of quarters through the year and how you see the alignment of supply to the financials that you're going to see. Like how much visibility you think is there now today relative to the visibility you saw during 2018?
其實我是代替David的Jon Demchick。我想更深入了解醫療器材中的靜脈輸液(IV)解決方案部分——或者說,藥物輸送(Medication Delivery)業務——並思考你們對今年前幾個季度的預測,以及你們如何看待供應與你們將看到的財務表現之間的匹配。例如,相較於2018年你們當時的能見度,你們認為目前的能見度有多高?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
We never met but welcome to our call. I'm going to take the first part of the question, and then I'll pass on to Jay, who will get into more of the financial impact. Listen, we found now that we're largely -- the inventory in the chain is largely balanced, meaning that while we see financial results or dollars coming in and the inventory levels at distributors, so sales out to hospitals and inventory is balanced. We saw that throughout Q4. We think that we have a stable market right now, and -- which made us conclude that we have not lost market share, our market share is stable. And some of the OEM contracts that we had spoken about are coming back a little faster, and we have some opportunities. So what you see in the progression of the quarters is that we have a very tough comp in the first quarter because in the quarter, if you remember last year, there was a significant amount of buy-in, a tough flu season was the reaction to the hurricane in late 2017. So this is a tough quarter for us to compare. But if you look across the other quarters and for the year, Medication Delivery will be a 6% business, which tells you that this is a well-established business, a stable business. And we have plans to continue to convert that. We have the launch of our new pump coming in. The new pump will drive more stats, will drive more volume, and the ability to capture those stats will be great.
我們雖然沒見過面,但歡迎加入我們的電話會議。我先回答問題的第一部分,接著我會交給Jay,他會更深入談財務影響。我們現在發現,通路中的庫存大致已達到平衡,也就是說,我們看到的財務結果或資金流入,與經銷商端的庫存水位、對醫院的出貨與庫存之間是平衡的。我們在第四季全程都看到這種情況。我們認為目前市場相當穩定——因此我們得出結論:我們並未流失市占率,我們的市占率是穩定的。而且我們先前提到的一些OEM合約回流速度比預期更快,我們也有一些機會。因此你在各季度的走勢上會看到:第一季的比較基期非常艱難,因為如果你還記得去年,同一季度有大量的提前備貨(buy-in);當時嚴重的流感季,加上2017年底颶風後的反應,都促成了那波備貨。所以這一季對我們來說是很難比較的一季。但如果你看其他季度以及全年,藥物輸送將是一個約6%成長的業務,這也說明這是一個成熟、穩定的業務。我們也有計畫持續推進轉換。我們即將推出新的幫浦產品。新幫浦將帶動更多裝機量(stats)、帶動更多出貨量,而我們捕捉這些裝機量的能力也會很強。
The other thing that makes this quite stable is we are 2 out of 3 GPOs signed. In one of them, we are 100% resigned with the IDNs. And we feel very comfortable about our position in the marketplace. And now let me pass on to Jay who'll talk a little bit more on the financial impact.
另外一個讓這項業務相當穩定的因素是:我們已與三大GPO中的兩家完成簽約。其中一家,我們已與IDN 100%完成續約。我們對自己在市場上的地位感到非常放心。現在我把時間交給Jay,請他再多談一些財務影響。
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Yes, just thinking about the IV therapy business, we did have a substantial buy-in in the first quarter of last year. That's -- it was roughly a $15 million positive sales impact in the first quarter. So recognizing this is a low single-digit end user demand, that was a -- that was certainly a departure which we've discussed in the past. And so as we look at our plans for the U.S. business with respect to IV therapy, you will see a decline in the first quarter this year into double digits. But then as we move to the back half of the year -- in the second quarter, it's a more normal quarter. And then in the back half of the year, we do have the benefit of easy comps in large part because of some of that inventory coming out of the channel. So really, that's the sequencing that we expect to see during the year.
是的,談到靜脈(IV)治療業務,去年第一季確實有相當可觀的提前備貨。那——大約在第一季帶來了1,500萬美元的正向銷售影響。因此,在終端使用者需求僅為低個位數成長的背景下,那確實是一個——我們過去也討論過——偏離常態的情況。所以當我們檢視今年美國IV治療業務的規劃時,你會看到今年第一季將出現兩位數的下滑。但接著進入下半年之前——第二季會是較正常的一季。而在下半年,我們將受惠於較容易的比較基期,主要是因為部分庫存會從通路中消化掉。因此,這就是我們預期全年會看到的節奏。
David Ryan Lewis - MD
David Ryan Lewis - MD
Okay. And actually, guys, this is David, I'm stepping in for Jon. Sorry about that. So 2 questions for me, Joe, just kind of more strategically. And the first one, obviously, is 2 focus items for Investors. The first is fluids, and I think you've addressed that for '19 and the first quarter. The second, obviously, is balance sheet deployment, Joe. How urgent are you feeling about deployment in 2019 to sort of get back to 5%? On one hand, I think about the headwinds in your business, BREVI and HD. You can almost get back to 5% just adjusting for those headwinds versus your '19 guidance. But how important is M&A to you this year to deliver your LRP targets in '20? And then for Jay, just thinking about margins. Obviously, you've talked about a margin opportunity of 300 basis points over the next 2 years, guiding to about 50 this year. How good do you feel about the ability to still deliver those margin targets into 2020 just relative to the '19 guide?
好的。各位,其實我是David,我來接替Jon。抱歉。Joe,我這邊有兩個問題,偏策略面。第一個,顯然是投資人關注的兩個重點之一。第一是輸液(fluids),我想你已經針對2019年與第一季做了說明。第二個顯然是資產負債表的資金運用(balance sheet deployment),Joe。你對於在2019年進行資金部署、以回到5%成長的急迫感有多高?一方面,我想到你們業務中的逆風因素,BREVI和HD。相較於你們2019年的指引,光是把這些逆風因素調整回來,你們幾乎就能回到5%。但今年對你而言,為了在2020年達成你們的LRP目標,併購(M&A)有多重要?另外給Jay,談到毛利率。你們提到未來兩年有300個基點的毛利率改善機會,今年指引大約是50個基點。相較於2019年的指引,你對於到2020年仍能達成那些毛利率目標的把握有多大?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
That was well orchestrated. So we've got 3 questions out of your call. You said only 2. But I'll -- those are good questions, and we're going to answer them properly.
這安排得很周到。所以你這通電話其實問了3個問題。你說只有2個。但我——這些都是好問題,我們會好好回答。
M&A. Listen, we continue very aggressively looking for opportunities. And I want you guys to think about not on a size based but more so on adjacencies and things that'll make sense for our company, for Baxter. It is -- don't mistake our aggressiveness in looking for targets with our discipline of really understanding the financials behind the returns for acquisition, which are unchanged. We are looking for molecules. We have -- and we'll require molecules in the marketplace to augment our Pharmaceuticals. We're interested in critical care. We're interested in many other areas that are adjacent to our business. Size is not the priority, but the ability to augment that. Will M&A be a great part of our LRP? Will augment our LRP. I'm still very confident that we have the ability to deliver the LRP. We've done M&A at the moment because we have $1.7 billion in new products coming in, in 2023, and that is still in the plans. And if you look at our new product development, sales contribution in the second half of 2018 was great. We have some really -- a lot of new products coming in. So we're confident in that. But I think augmented with adjacencies M&A. And don't be hung up on size. Some may be a little larger than others, but we are working intensively. But I want our investors to understand. I would like to underscore the fact that the returns and the financial returns for shareholders is very, very important to us, so we would not do a deal that is in the fringes or negatively will impact our return to our shareholders. And I'll pass on to Jay on the balance sheet.
併購(M&A)。聽著,我們仍在非常積極地尋找機會。我希望各位不要只用規模來看,而是更多從相鄰領域(adjacencies)以及哪些對我們公司、對Baxter有意義的方向來思考。不要把我們積極尋找標的,誤解為我們在紀律上有所鬆動;我們對於理解併購報酬背後的財務回報要求並沒有改變。我們在尋找分子(molecules)。我們需要——而且會要求——市場上的分子來強化我們的製藥(Pharmaceuticals)業務。我們對重症照護(critical care)有興趣。我們也對許多與我們業務相鄰的其他領域有興趣。規模不是優先事項,重點是能否帶來增補效益。併購會是我們LRP的重要一部分嗎?它會增補我們的LRP。我仍然非常有信心,我們有能力達成LRP。我們目前之所以能做併購,是因為到2023年我們將有17億美元的新產品導入,而這仍在計畫之中。如果你看我們新產品開發在2018年下半年的銷售貢獻,表現非常好。我們有一些真的——很多新產品即將推出。所以我們對此很有信心。但我認為還可以透過相鄰領域的併購來增補。不要執著於規模。有些可能比其他案子大一些,但我們正在密集推進。不過我希望投資人理解。我想強調的是:對股東的回報與財務報酬對我們非常、非常重要,因此我們不會做那種處在邊緣、或會對股東回報造成負面影響的交易。接下來我把時間交給Jay談資產負債表。
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Yes, great. Great. Yes, in terms of the margin but also in terms of actual sales growth, I do think it's important, David. You referenced something. Our operational sales growth this year of 3% to 4%, as you know, exclude the impact of cyclo. But it does include 2 important impacts. One is BREVIBLOC, we discussed this extensively, roughly $75 million. But then, we've also talked about this idea of historically exiting lower-margin businesses. And one of the items we've pursued is kind of shrinking certain areas where there was little margin in our in-center HD business. But that's roughly a $60 million impact. So thinking exclusively about sales growth, the 3% to 4% includes within it roughly 130 basis points of impact that depress it in 2019 relative to the normalized rate of growth we'll expect to see going forward.
是的,很好。很好。是的,就毛利率以及實際銷售成長而言,我確實認為這很重要,David。你提到了一點。如你所知,我們今年3%到4%的營運銷售成長不包含cyclo的影響。但它確實包含兩個重要影響。其一是BREVIBLOC,我們已經深入討論過,約7,500萬美元。另外,我們也談到過這個概念:歷來退出較低毛利的業務。我們採取的其中一項措施,是在我們院內HD業務中,縮減某些毛利很低的領域。但這大約帶來6,000萬美元的影響。因此,若只看銷售成長,3%到4%之中包含約130個基點的影響,使其在2019年相較於我們預期未來將看到的常態化成長率有所壓低。
The second item, as it relates to margin expansion, this is one area we have been incredibly focused on over the last several years. And this year, we'll see further margin growth. But I will highlight that, this year, we're faced with a number of very significant headwinds on the path to delivering this margin expansion. Cyclophosphamide, that's roughly 1% of margin impact. BREVIBLOC, that's -- oh, sorry, BREVIBLOC is roughly 50 basis points of margin impact, and I should say cyclo is roughly 50 basis points. And then foreign exchange is roughly 30 basis points.
第二點,關於毛利率擴張,這是我們過去幾年極度聚焦的一個領域。而今年,我們將看到進一步的毛利率成長。但我要強調的是,今年在實現這項毛利率擴張的過程中,我們面臨多項非常顯著的逆風。Cyclophosphamide,約帶來1%的毛利率影響。BREVIBLOC,約—喔,抱歉,BREVIBLOC約帶來50個基點的毛利率影響;我也要說,cyclo約為50個基點。另外,外匯約為30個基點。
So if we put these items together, we're talking about, again, 130 basis points of headwinds that we fight through on the way to the margin expansion that we'll deliver. This year, we had a number of headwinds as well. We've discussed those in the past. And we were able to, again, deliver nice margin expansion in the face of that. So we don't point to headwinds as a reason to not deliver margin expansion. But again, it does depress margin expansion relative to the normal rate of growth.
因此把這些項目加總起來,我們談的是—同樣地—約130個基點的逆風,而我們將在克服這些逆風的同時實現我們要交付的毛利率擴張。今年我們也有多項逆風。我們過去已討論過。而我們也能夠再次在此情況下交出不錯的毛利率擴張。所以我們不會把逆風當作無法交付毛利率擴張的理由。但同樣地,這確實會使毛利率擴張相較於常態成長率有所壓低。
Operator
Operator
And the next question comes from Robbie Marcus of JPMorgan.
下一個問題來自摩根大通(JPMorgan)的Robbie Marcus。
Robert Justin Marcus - Analyst
Robert Justin Marcus - Analyst
Jay, maybe I can follow up on that. The guidance came in, I think, pretty good on the top line, especially considering all the headwinds that weren't factored into Street models. But first quarter came in a little bit lighter. So maybe you can walk us through the puts and takes of the cadence through 2019 and maybe some of the product launches or different factors that give you confidence in that second half acceleration.
Jay,我或許可以就此追問一下。我認為你們的指引在營收端表現相當不錯,尤其考量到有許多逆風並未納入華爾街模型。但第一季看起來稍微偏弱一些。所以也許你可以帶我們了解一下2019年各季節奏的利多利空,以及一些產品上市或其他因素,讓你們對下半年加速成長有信心。
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Yes, you -- Robbie, you're correct. This is a meaningful acceleration that we'll see towards the back half of the year -- in the back 3 quarters, I should say. And there are a number of specific items impacting the first quarter growth. So we pointed to operational sales growth of 1% to 2%. But included in that, BREVIBLOC, the biggest impact that we're going to see is, I believe, in the first quarter. It's roughly $35 million in sales, roughly 1.3 percentage points of growth. The IV buy-in, so we did see a very significant, heightened buying pattern in the IV business. I referenced it moments ago. That's about $15 million or roughly 50 basis points of growth. And then in-center HD, this exit that we pursued, is another factor that's depressing Q1 sales growth. That's roughly $15 million. And so again, as we look at this first quarter growth of 1% to 2%, we have almost 2.5 points of sales growth headwinds that are most pronounced in the first quarter of the year. Now transitioning that to an EPS discussion, quite simply, $0.05 of BREVIBLOC, $0.01 of cyclo, $0.03 of FX. And by the way, FX is more of a first half phenomena than a second half phenomena. You put these items together and it's significantly impacting the first quarter EPS. But furthermore, we have a number of benefits that start to accrue to the second half of the year. We have the easier comps in the U.S. Medication Delivery in that business that I mentioned earlier. And then furthermore, we start to see the benefit of some of the new products and the acceleration there. Joe in his script referenced some of the great progress that we're making. We're pleased really across the aboard, but it's not overnight that these products come to bear. And so we do see a bigger impact in the second half of the year on the way to an even bigger impact in 2020.
是的,你—Robbie,你說得沒錯。我們將在今年後半段—更精確地說,在後三個季度—看到一個有意義的加速。而有多個具體項目正在影響第一季的成長。因此我們指出營運銷售成長為1%到2%。但在其中,BREVIBLOC,我們將看到的最大影響,我認為會出現在第一季。約3,500萬美元的銷售額,約1.3個百分點的成長。IV買入(buy-in),因此我們確實在IV業務看到非常顯著、偏高的採購模式。我剛剛提到過。那大約是1,500萬美元或約50個基點的成長。另外,院內HD方面,我們推動的這項退出,也是在壓低第一季銷售成長的另一個因素。約1,500萬美元。因此同樣地,當我們看第一季1%到2%的成長時,我們有將近2.5個點的銷售成長逆風在一年之中於第一季最為明顯。現在把這轉到EPS的討論,很簡單:BREVIBLOC為0.05美元,cyclo為0.01美元,外匯為0.03美元。順帶一提,外匯更像是上半年現象,而不是下半年現象。把這些項目加總起來,對第一季EPS造成顯著影響。但此外,我們有多項效益會在下半年開始逐步顯現。我們在美國藥物輸送(Medication Delivery)業務方面,將迎來我先前提到的較容易的比較基期。此外,我們也開始看到一些新產品帶來的效益以及那裡的加速。Joe在他的講稿中提到我們取得的一些重大進展。我們確實在各方面都很滿意,但這些產品的效益並非一夕之間就會顯現。因此我們確實看到下半年影響更大,並在邁向2020年時帶來更大的影響。
Robert Justin Marcus - Analyst
Robert Justin Marcus - Analyst
That's really helpful. One other thing I wanted to dive into is it looks like the pharma business did very well in the quarter even when backing out the generic headwinds. I think it's a part of the business a lot of people don't understand the underlying drivers. Can you give us a little bit more insight into what's driving the outperformance there and how to think about the key growth drivers in '19?
這真的很有幫助。我還想深入了解另一件事:看起來製藥業務在本季表現非常好,即使把學名藥的逆風剔除也是如此。我認為這是很多人不太理解其底層驅動因素的一部分業務。你能否多分享一些洞見,說明是什麼在推動那裡的超預期表現,以及如何看待2019年的關鍵成長驅動因素?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Robbie, the performance is being driven by several factors. Let me start highlighting the success of the molecules that we've been launching internally from Baxter. And those are special molecules, not the molecules themselves, but the delivery of the API. And the second is our premix. So premix is the substitute for when we have shortages. We've made great efforts to substitute some of our Mini-Bag Plus product lines in the marketplace by premixes. And the premixes are more effective and even safer way of delivering the medication. And that is doing extremely well. The growth is fantastic. We're moving up by 30-plus percent of growth in premixes. So I know that we've both had Medication Delivery and the recap of and recover of our Mini-Bag Plus and Mini-Bags business. But some of that, we actually prefer the conversion into premixes, which has been extremely successful. The margins are higher by 20%, 30%, and we think that, that is the way to go. So our Pharmaceuticals business is doing extremely well. We have more molecules coming up in '19 and '20, and we feel that, that business is finally taking off ex this cyclo and BREVIBLOC, which eventually will be something of the past and we can move on to the new Pharmaceuticals business, which is leadership in generic injectables with novel ways of delivering the medication. Thank you.
Robbie,這項表現是由幾個因素所驅動。我先強調我們在Baxter內部推出的分子(molecules)所取得的成功。而那些是特殊的分子—不是分子本身,而是API的輸送方式。第二是我們的預混(premix)。因此,當我們出現短缺時,預混是替代方案。我們已投入很大努力,透過預混在市場上替代我們部分Mini-Bag Plus產品線。而預混是一種更有效、甚至更安全的給藥方式。而這項業務表現非常好。成長非常驚人。我們的預混成長率提升到30%以上。所以我知道我們同時談到了藥物輸送(Medication Delivery)以及我們Mini-Bag Plus與Mini-Bags業務的回顧與復甦。但其中一部分,我們其實更偏好轉換為預混,而這已非常成功。毛利率高出20%、30%,而我們認為這是正確方向。因此我們的製藥業務表現非常好。我們在2019年與2020年還會有更多分子推出,我們也覺得該業務終於開始起飛—若不計這個cyclo與BREVIBLOC;這些最終都會成為過去式,我們可以轉向新的製藥業務,也就是以創新的給藥方式在學名注射劑領域取得領導地位。謝謝。
Operator
Operator
And our next question comes from Bob Hopkins of Bank of America.
我們的下一個問題來自美國銀行(Bank of America)的 Bob Hopkins。
Robert Adam Hopkins - MD of Equity Research
Robert Adam Hopkins - MD of Equity Research
Just 2 questions for me. One is a clarification. And I'm sorry, if I missed this, but are you guys today explicitly reiterating your 2020 operating margin, EPS and rev growth targets that you set last year?
我這邊只有兩個問題。第一個是釐清一下。抱歉如果我漏聽了,但你們今天是否明確重申去年所設定的 2020 年營業利益率、每股盈餘(EPS)以及營收成長目標?
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Yes, Bob. Yes, we are. There's no changes to those guidance numbers.
是的,Bob。是的,我們是。那些指引數字沒有任何變動。
Robert Adam Hopkins - MD of Equity Research
Robert Adam Hopkins - MD of Equity Research
Okay. And then the other thing I want to ask about was just Medication Delivery. We've talked about it a little bit here, but, obviously, that was a division that caused you trouble for 2 quarters of 2018, and now your guidance for this year is for 6% growth. And I realize some of that is easy comps, but it just seemed a little higher guidance than I anticipated given what happened in 2018 and also given your comments about the tough competitive landscape on the pump side. So maybe you could walk through a little bit what gives you confidence in that 6% from a new product perspective because even comp adjusted, you're projecting accelerated growth here in 2019.
好的。那我想問的另一件事是藥物輸送(Medication Delivery)。我們在這裡稍微談到一些,但很明顯,這個事業部在 2018 年有兩個季度讓你們遇到麻煩,而你們今年的指引是成長 6%。我知道其中一部分是因為比較基期較容易,但考量 2018 年發生的情況,以及你們對幫浦端艱困競爭環境的評論,這個指引看起來比我預期的要高一些。所以也許你們可以從新產品的角度,稍微說明一下是什麼讓你們對這個 6% 有信心;因為即使調整比較基期,你們仍在 2019 年預測這裡的成長會加速。
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
So we are definitely getting some benefits from the recapture or the acceleration campaigns with respect to Mini-Bag, Mini-Bag Plus and then some stability in the LVPs. So the reality is, because of the rebates that took place in a number of our product lines, we are able to see above-market growth rates in certain product categories. As we referenced in the call, we were pleased to see some of the progress that we made in those areas in the fourth quarter of 2018. So very, very solid early signs of the recapture campaign paying dividends. And that will continue to pay dividends. Again, above-market growth barring the first quarter issue. So that's one factor. The second factor that comes into play is we do start to see accelerated performance on the EU pump -- the version 9 of our Spectrum pump, which starts to accelerate towards the back half of the year. We've been pleased with the reception of this pump in the marketplace, well received by clinicians around the U.S. So very positive reception. But their sales cycle has been longer than we expected. And so as a result of that, we'll start to pay that off in 2019. We've got a line of sight to the pipeline that gives us confidence that we'll be able to do that. So you put those things together, and like I said, this is a -- this is one where we have a high level of confidence in the acceleration that takes place. And then furthermore, we do have some easier comps in the second half of the year for it certainly as we look at performance there.
我們確實正從回收(recapture)或加速推進活動中獲得一些效益,特別是針對 Mini-Bag、Mini-Bag Plus,以及 LVP(大容量輸液)的一些穩定性。所以現實是,由於我們多條產品線進行了回扣(rebates),我們得以在某些產品類別看到高於市場的成長率。如同我們在電話會議中提到的,我們很高興看到 2018 年第四季在這些領域取得的一些進展。因此,回收活動開始帶來成果的早期跡象非常、非常扎實。而且這將持續帶來成果。再次強調,除了第一季的問題之外,我們的成長將高於市場。這是一個因素。第二個因素是,我們開始看到 EU 幫浦——也就是我們 Spectrum 幫浦第 9 版——的表現加速,並在下半年加速更為明顯。我們對這款幫浦在市場上的反應感到滿意,在美國臨床端的接受度很高,反應非常正面。但其銷售週期比我們預期更長。因此,這部分將在 2019 年開始反映出來。我們對管線(pipeline)的能見度讓我們有信心能做到。把這些因素放在一起,如我所說,這是一個——我們對於 2019 年出現的加速成長有很高信心的領域。此外,當我們看下半年表現時,確實也會有一些較容易的比較基期。
Clare Trachtman - VP of IR
Clare Trachtman - VP of IR
The only other comment I would make there, too, as well is we are going to see some acceleration outside the U.S. as well as we anniversary some of the comps. As you remember, we took some of that volume to the U.S., and now we have successfully -- we are going to successfully bring some of that volume back to those Latin American markets as well.
另外我還想補充的是,隨著我們進入某些比較基期的周年,我們也會看到美國以外市場的加速。如你所記得的,我們曾把部分產量轉到美國,而現在我們已經成功——並且將會成功把其中一部分產量帶回拉丁美洲那些市場。
Operator
Operator
And our next question comes from Matt Taylor of UBS.
我們的下一個問題來自瑞銀(UBS)的 Matt Taylor。
Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices
Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices
So the first one I wanted to ask about was the renal business. There was a little bit of a tick-up here, and you highlighted now you've got all your cyclos around the world and more people using them. Can you talk about assumptions for 2019 in terms of any pickup that you could see in PD because of the cyclos? And then I'd love to get a little bit more color on how you're feeling about on-demand PD looking into 2020 and what kind of impact that can have.
我第一個想問的是腎臟業務。這裡有一點點回升,而你們也強調現在全球各地都已部署你們的 cycler(腹膜透析機),而且有更多人正在使用。你能談談 2019 年的假設嗎?也就是因為這些 cycler,你們在 PD(腹膜透析)方面可能看到的任何回升?另外我也想更了解你們對按需 PD(on-demand PD)展望到 2020 年的看法,以及它可能帶來什麼樣的影響。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
I'll take that. Our Renal Care, 2% to 3% is our guidance in 2019. And I just want to give a little color why it's 2% to 3% and then how do we connect the PD patient growth to it. We consciously are walking away from business that were unprofitable in some geographies, primarily bloodlines, and was a large volume of product. So our HD business is artificially depressed because our decision -- we were making no money. As a matter of fact, we're losing money in that business, and it was a good thing that we're not going to be in that business anymore. Moving to the PD business, we're still looking between 5% or 6% in patient growth. This is a very healthy business. The best geographies in the world right now are North America as well as parts of Asia, Japan and China. We had very successful launch of CLARIA with Sharesource, relaunch in parts of Europe, a very difficult time we had with the privacy issues in Europe. And now we overcame that issue in many geographies in Europe. And we're starting to see CLARIA with Sharesource, which is a different cycler similar to the HOMECHOICE, the old HOMECHOICE in U.S., but updated with the software for monitoring. So that is now being used in several different countries in Europe. But we struggled in the beginning with the privacy. We got to understand how difficult it is to operate in Europe with software that does home monitoring. But now that's going well.
我來回答。我們 2019 年對腎臟照護(Renal Care)的指引是 2% 到 3%。我想補充一些背景,說明為什麼是 2% 到 3%,以及我們如何把 PD 病患成長與之連結。我們有意識地在某些地區退出不具獲利性的業務,主要是血路(bloodlines),而那是一個出貨量很大的產品。因此,我們的 HD(血液透析)業務因為這個決策而被「人為」壓低——我們當時根本賺不到錢。事實上,我們在那個業務上是虧錢的,而不再做那個業務其實是件好事。轉到 PD 業務,我們仍然預期病患成長在 5% 或 6% 之間。這是一個非常健康的業務。目前全球最好的地區是北美,以及亞洲的部分地區、日本和中國。我們在歐洲部分地區成功重新推出搭配 Sharesource 的 CLARIA;先前我們在歐洲因隱私問題經歷了一段非常困難的時期。而現在我們已在歐洲許多地區克服了這個問題。我們開始看到搭配 Sharesource 的 CLARIA——這是一種不同的 cycler,類似於美國舊款 HOMECHOICE,但軟體已更新,可用於監測。因此,這套系統目前已在歐洲多個不同國家使用。但一開始我們確實在隱私方面遇到阻礙。我們也理解到,在歐洲要運作具居家監測功能的軟體有多麼困難。但現在進展得很順利。
I'd point to Japan. Japan, the KAGUYA business in Japan is doing extremely well. We already have 1,000 patients on therapy there. We expect to really accelerate that business in '19 and '20. So expect 5% to 6% patient growth, very healthy business in the U.S. Our partnership with DaVita is going well, great partner and great customer.
我也想提到日本。日本的 KAGUYA 業務表現非常好。我們在那裡已經有 1,000 名病患接受治療。我們預期在 2019 年和 2020 年會大幅加速這項業務。所以請預期病患成長 5% 到 6%;在美國這也是非常健康的業務。我們與 DaVita 的合作進展良好,他們是很棒的合作夥伴,也是很棒的客戶。
Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices
Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices
Great. And any additional color you can talk about in terms of the pipeline with on-demand PD?
很好。那關於按需 PD 的研發管線(pipeline),你還能補充一些細節嗎?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Well, we just have few patients lined up to start receiving the therapy. We have one that has started and is going well so far. Early to say, but it is something. This is a very classic Baxter stance. We say something, we do something. We cannot to say stuff and not do it. So we put our patient on therapy like we promised. We're going to work hard on that therapy. It's complex because you're making the drug in people's homes, but it's going well so far. And I tell you, we're going to have several iterations of this technology going forward because this is going to be almost a comparison to what the electric car was 7, 8 years ago. You start and you start evolving, evolving. And we're going to evolve this technology. We'll continue to be the leaders in home therapy for peritoneal dialysis.
嗯,我們已安排少數病患準備開始接受這項治療。其中有一位已經開始了,到目前為止進展良好。現在下結論還太早,但這確實是一個開始。這是非常典型的 Baxter 風格。我們說到就做到。我們不能只說不做。所以我們如同承諾的,讓病患開始接受治療。我們會在這項治療上非常努力。它很複雜,因為你是在病患家中製備藥物,但到目前為止進展良好。我也告訴你,我們未來會對這項技術進行多次迭代,因為這幾乎可以類比電動車在 7、8 年前的狀態。你先開始,然後不斷演進、演進。而我們也會持續演進這項技術。我們將持續成為腹膜透析居家治療的領導者。
Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices
Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices
Great. And can I just ask one follow-up on the pharma business? You mentioned some of the dynamics before, but I was hoping you could be more specific about kind of the both number of molecules you're launching in '19 versus '20 and really thinking about the Claris dynamic there. I mean, should we see some acceleration in terms of the molecules and the growth in '20?
很好。我可以就製藥業務再追問一個問題嗎?你先前提到一些動態,但我希望你能更具體說明,例如你們在 '19 相較於 '20 推出的分子數量,以及那邊 Claris 的動態。我的意思是,到了 '20,我們是否應該看到分子數量與成長方面的加速?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Well, let me -- let's divide this in pieces. We have Claris molecules, which were part of our plan for Claris. And as you know, we have the warning letter for the facility. We're doing everything that we're -- we promised to do to the FDA. We will be inspected couple of times before we can get clearance or VAI for that location. So our focus right now for Claris is to be able to get that facility cleared of the warning letter, and all the efforts that we promised the agency are being done. We also have a contingency planned for that plant because we would like to have plan B, and our plan B is for most of our products that will be sold in the U.S., we would have CMOs or backups so we can continue operation if something doesn't work. It means that we're working everything that -- every angle that we can to make sure there's no disruption to our plan because of the warning letter at Claris. So this is -- this addresses Claris.
好,我們把這個拆成幾個部分來談。我們有 Claris 的分子,這些原本就是我們針對 Claris 的計畫之一部分。而如你所知,我們的該設施收到 FDA 的警告信。我們正在做所有我們向 FDA 承諾要做的事情。在我們能取得該地點的核准或 VAI 之前,會被檢查好幾次。因此,我們目前對 Claris 的重點是讓該設施解除警告信,並且我們向主管機關承諾的所有努力都在進行中。我們也為該工廠規劃了應變方案,因為我們希望有 B 計畫;我們的 B 計畫是,對於大多數將在美國銷售的產品,我們會有委外製造商(CMO)或備援,以便在某些事情不如預期時仍能持續營運。這表示我們正從各個角度著手,確保不會因 Claris 的警告信而使我們的計畫受到干擾。所以這一段是在說明 Claris。
The other molecules that we have, and we have some important molecules launched at the end of '19 and '20, they're really breakthrough molecules. Not that the molecule itself is breakthrough, but the delivery system of the molecule is a premix and nobody has that in the market. I'm not going to give the name of the molecule, but I'm telling you we have some really interesting stuff going on.
至於我們其他的分子,我們在 '19 年底與 '20 年會推出一些重要分子,它們確實是突破性的分子。並不是分子本身是突破性,而是該分子的給藥系統是預混(premix),而市場上沒有人有這樣的產品。我不會說出分子的名稱,但我可以告訴你,我們正在推進一些非常有意思的事情。
The other thing is we have molecules that were launched last year. We have a few more launching this year. There was a launch last year. I have to say one of them, and I'm not going to give the name of the molecule, has done extremely well with 40% higher sales than our estimates for last year. So that will continue to do well. So our plan for Pharmaceuticals is absolutely offset and leave in the past cyclophosphamide and BREVIBLOC and things that were -- the chief products for the company a few years ago, we're moving into -- as we said, we're going to add almost 70 molecules to our portfolio and about double that the ways to deliver those molecules. And we're going to do this in a multitude of regions like we promised last year, and we are on plan to do it. As I said, we have an important molecule that hopefully will be launched by the end of '19, and we'll announce that properly when that happens.
另外,我們也有一些分子是在去年推出的。今年還會再推出幾個。去年有一次上市。我必須說,其中一個(我不會說出分子名稱)表現非常好,去年的銷售額比我們的估計高出 40%。所以它會持續有很好的表現。因此,我們的製藥事業計畫就是要完全抵消並把 cyclophosphamide、BREVIBLOC 等幾年前公司的主力產品留在過去;我們正在轉向——如同我們所說——我們將在產品組合中新增將近 70 個分子,並把這些分子的給藥方式增加到大約兩倍。而且我們會如同去年承諾的,在多個地區推進,我們正按計畫進行。如我所說,我們有一個重要分子希望能在 '19 年底前上市,屆時我們會在發生時適當對外公告。
Operator
Operator
And our next question comes from Vijay Kumar of Evercore ISI.
下一個問題來自 Evercore ISI 的 Vijay Kumar。
Vijay Muniyappa Kumar - MD
Vijay Muniyappa Kumar - MD
So a couple of, I guess, guidance, housekeeping questions here. Is the guidance assuming any contribution -- or I guess I shouldn't say contribution, the resolution of FDA warning letter on Claris? And I'm curious, Jay, you mentioned the LatAm business coming back for IV fluids. That happens to be a tender business. I'm just curious, have you signed any tenders? Do you have any visibility?
我有幾個我想算是指引方面、例行性的問題。這份指引是否假設 Claris 的 FDA 警告信會有任何進展——或者我不該說貢獻,而是說警告信的解決?另外我也好奇,Jay,你提到拉丁美洲的靜脈輸液(IV fluids)業務正在回升。那剛好是投標型業務。我想問,你們有簽下任何標案嗎?你們有任何能見度嗎?
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
So from an FDA standpoint, there's no resolution assumed in our 2019 numbers for resolution of the Claris warning letter. Obviously, that becomes an important component of our 2020 numbers. So to the extent that we get that resolved along the time frame we expect, then the long-range plans that we have are intact with no change. We're looking for mitigation tactics in the event that, that does not occur. But as we look at 2020, that would be an important component for us to get resolved. As it relates to Latin America, yes, certainly there's a different dynamic in terms of tendering in Latin America versus certain other markets. And so we have moved some volumes back to Latin America. We have clear line of sight to sales performance and where that's going to go. And in some cases, tenders have been won. But as opposed to going through that in a lot of detail, what I will tell you is we have a high level or a solid level of confidence in our ability to deliver some of the IV sales in the Latin America business.
就 FDA 的角度而言,我們的 2019 年數字並未假設 Claris 警告信會獲得解決。顯然,這會成為我們 2020 年數字中的一個重要組成。因此,只要我們能在預期的時間範圍內解決它,我們的長期計畫就能維持不變。若未能如期發生,我們也在尋找緩解措施。但就 2020 年而言,解決這件事對我們會是重要的一環。至於拉丁美洲,沒錯,拉丁美洲的投標動態確實與其他某些市場不同。因此我們已把部分出貨量移回拉丁美洲。我們對銷售表現以及其走向有清楚的掌握。而且在某些情況下,我們已贏得標案。不過與其在這裡詳述,我想說的是:我們對於在拉丁美洲業務中交付部分 IV 銷售的能力,具有高度或相當穩健的信心。
Vijay Muniyappa Kumar - MD
Vijay Muniyappa Kumar - MD
Yes, that's helpful, Jay. And just one follow-up on the interest expense guidance. And it looks like interest expense is going up. Is there any -- I'm just curious, what does it implicate for cash balance or capital deployment just because this is ticking up?
是的,這很有幫助,Jay。另外再追問一個關於利息費用指引的問題。看起來利息費用在上升。我只是好奇,這上升是否意味著對現金餘額或資本配置會有任何影響,因為這項目正在增加?
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Yes, we have a -- we do have a higher interest expense year-over-year. So that's a few cents of impact. And there's really 2 factors in play. One is the rising interest rate environment. But more than that, it's we have repurchased a significant number of shares. As we said in the past, if we have opportunities to buy shares in the market and it's below the intrinsic value, we take advantage of that. In the fourth quarter, we did see a dislocation. We saw a fairly meaningful movement in the stock price, but our long-term valuation of the shares was very much intact. We took the opportunity to produce a number of vehicles to repurchase shares. That has a share benefit in terms of share count for the full year 2019. There is an offset to that, which is increased interest expense. Now as we look at the overall position for Baxter, the net debt situation, we are still significantly below 1 turn of net debt-to-EBITDA. And while we've said our long-term target is 2x net debt-to-EBITDA, what I will tell you is, I believe we have more -- our main goal is to maintain a solid investment-grade credit rating, and I do believe we have more flexibility than that as we look at further capital deployment. So it doesn't -- the share repo that we pursued in the fourth quarter really does not impact our business development, our capital deployment strategy to any significant extent going forward. But it's a fair point about increased interest expense.
是的,我們的利息費用確實較去年同期更高。因此會有幾美分的影響。主要有兩個因素。第一是利率上升的環境。但更重要的是,我們回購了相當數量的股票。如同我們過去所說,如果我們有機會在市場上以低於內在價值的價格買回股票,我們就會把握。在第四季,我們確實看到價格脫鉤的情況。我們看到股價有相當明顯的波動,但我們對股票的長期估值仍然非常穩固。我們把握機會,透過多種工具來回購股票。這在 2019 全年會對股數(share count)帶來有利影響。但相對應的抵銷因素就是利息費用增加。現在,從 Baxter 的整體狀況來看,我們的淨負債水準仍顯著低於淨負債對 EBITDA 的 1 倍。雖然我們說過長期目標是淨負債對 EBITDA 2 倍,但我想說的是:我認為我們更主要的目標是維持穩健的投資等級信用評等,而且我也相信在進一步的資本配置方面,我們的彈性比那個目標所暗示的還要大。因此,我們在第四季進行的股票回購,對於未來我們的業務發展與資本配置策略,並不會造成任何顯著影響。不過你提到利息費用增加,確實是個合理的觀察。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
I just want to, Vijay and folks, to underscore what Jay just said. We had said that we were not going to let cash sit in the balance sheet unused. So we're going to return that to the shareholders in a way that we can make the most out of it. So ideally, we would like to buy more companies and spend money in M&A. But if we don't find the target with the right return, we're going to return money to shareholders in the other 2 vehicles that we have, which are share repurchase and dividends. So I want to make sure that people understand that those 3 vehicles can be -- are not mutually exclusive. They can be done concurrently. But we will accelerate one versus the other as we progress. As I said, money will not sit in the balance sheet unused.
我只是想,Vijay 以及各位,強調一下 Jay 剛才說的話。我們之前說過,我們不會讓現金閒置在資產負債表上而不使用。因此,我們會以能把它效益最大化的方式把它回饋給股東。理想情況下,我們希望收購更多公司,並在併購(M&A)上投入資金。但如果我們找不到具備合適報酬的標的,我們就會透過另外兩種工具把資金回饋給股東,也就是庫藏股回購與股利。所以我想確保大家理解,這三種工具——並非互相排斥。它們可以同時進行。但隨著我們推進,我們會加速其中一項相對於另一項。如我所說,資金不會閒置在資產負債表上而不使用。
Operator
Operator
And the next question comes from Larry Keusch with Raymond James.
下一個問題來自 Raymond James 的 Larry Keusch。
Lawrence Soren Keusch - MD
Lawrence Soren Keusch - MD
Joe, I obviously caught the comments relative to share being stable in IV solutions. I think one concern that investors have is that as we go through contracting processes and contract renewals, given some of the pricing around the spot market, et cetera, that, that pricing overall could start to come down. So I was hoping you could perhaps provide a little bit of color. And I guess in that, maybe some thoughts around just given the tremendous job that you guys have done with creating redundancies for supply, how that also resonates and factors into some of those discussions.
Joe,我顯然有聽到你們關於 IV 解決方案市占率保持穩定的評論。我想投資人有一個擔憂是,當我們經歷合約簽訂流程與合約續約時,考量到現貨市場的一些定價等等,整體定價可能會開始下滑。所以我希望你或許可以提供一些補充說明。另外我想,在這之中,也請談談:鑑於你們在建立供應冗餘方面做得非常出色,這如何在那些討論中產生共鳴並被納入考量。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Listen, we were not the benefactors of the spot market sale. Because when we end up having -- before we create all this flexibility in our supply chain in Americas, which today is second to none, we have that ability. It's so strong that we can guarantee with penalties to our customers the contracts that we supply them product, okay? But when we didn't have -- not have that, the other -- the competitors who were selling that product to our customers were selling sometimes in the spot market with higher prices. So we're not the ones who mostly benefit from that. So I would say pricing in the markets are established by contracts. We have stable contracts and a stable share. But pricing is a function of competitiveness in that. So we'll always be competitive in the marketplace. But we have what most companies today competing with us don't have. We have volume of manufacturing, but we have redundancy in plan. Think about where we're now approved to sell into the U.S. We can sell our -- out of -- our plants in the Carolinas. We can sell in the U.S. products made in Ireland, products made in Mexico and products made in Brazil. So we can, with the flip of a switch, very quickly build inventory contingencies across the Americas. And I think that is a very important position. So how does the price play in this is that, listen, we don't control price other than negotiations which are given -- who are between us and our customers. We did not benefit from the spot markets. So if you're thinking about seeing a decline in price in our contracts in 2019, those will not be there because we're not the ones who jacked up the price for a spot sale and took advantage of that.
聽著,我們並不是現貨市場銷售的受益者。因為在我們於美洲建立起這些供應鏈彈性之前——而我們今天的能力可說是首屈一指——我們現在具備那樣的能力。它強到我們可以在合約中對客戶做出供貨保證,甚至附帶違約罰則,確保我們供應他們產品,好嗎?但在我們還沒有——沒有那樣能力的時候,其他——那些把產品賣給我們客戶的競爭對手,有時會在現貨市場以更高的價格出售。所以主要受益的並不是我們。因此我會說,市場上的定價是由合約所建立的。我們有穩定的合約與穩定的市占率。但價格取決於其中的競爭態勢。所以我們在市場上會一直保持競爭力。但我們擁有多數目前與我們競爭的公司所沒有的東西。我們有製造量能,但我們也有產能配置的冗餘。想想我們現在獲准銷往美國的來源:我們可以從卡羅萊納州的工廠出貨。我們也可以在美國銷售由愛爾蘭製造、墨西哥製造以及巴西製造的產品。所以我們可以在一鍵切換之下,非常快速地在整個美洲建立庫存備援方案。我認為這是非常重要的地位。那麼價格在這裡如何發揮作用?聽著,我們除了透過與客戶之間的談判之外,並不控制價格。我們沒有從現貨市場中受益。所以如果你在想 2019 年我們合約價格會下滑,那不會發生,因為我們不是那個在現貨銷售中把價格拉高、並藉此占便宜的人。
Lawrence Soren Keusch - MD
Lawrence Soren Keusch - MD
Okay, perfect. And just one clarification and then a follow-up. The clarification is the -- I know you worked hard with the FDA to get clearance for a lot of those facilities to bring supply into the U.S. I just want to make sure that those are permanent approvals to bring supply in. And then the second question, Joe, I wanted to just touch on M&A perhaps in a slightly different way, which is, obviously, Amy Wendell has come on to the Board of Directors. She is somebody that you've worked with for a long time. She's been very, very impactful at Covidien relative to the M&A strategy. And so I just wanted to pick your brain a little bit on the implications of her joining the board.
好的,完美。再一個釐清,然後一個追問。釐清的是——我知道你們和 FDA 很努力,讓許多設施取得許可把供應引進美國。我只是想確認,這些把供應引進美國的核准是否都是永久性的。第二個問題,Joe,我想用稍微不同的角度談談併購(M&A):顯然 Amy Wendell 已加入董事會。她是你合作很久的人。她在 Covidien 的併購策略方面影響非常、非常大。所以我想請你談談她加入董事會所帶來的意涵。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Okay. So listen, going back to the first part of the question in terms of what is permanent. Mexico is permanent. Brazil is temporary right now, going to permanent after a second inspection that we're expecting from the FDA shortly. Ireland is permanent. And we're going to eventually hook up Canada as well as soon as we line up inspections from the FDA. But if you think about Mexico, Mexico being permanent for us, that's a humongous amount of volume that we can bring into the U.S. and divert into other places in Latin America as we wish. So there's a lot of flexibility. So Mexico broadly, if you think about 100% flexibility, Mexico brought to us 85% of flexibility to the supply chain. And the other 15% were brought by Ireland and eventually when Brazil gets permanent importation status, which will happen in 2019.
好的。那麼,先回到問題的第一部分,關於哪些是永久性的。墨西哥是永久性的。巴西目前是暫時性的,等到我們預期 FDA 很快會進行的第二次稽查之後,就會轉為永久性。愛爾蘭是永久性的。而我們最終也會把加拿大納入,一旦我們與 FDA 排定稽查時程即可。但如果你想想墨西哥,墨西哥對我們而言是永久性的,這代表我們可以引進美國的量非常龐大,並且也能依我們意願分流到拉丁美洲其他地區。所以彈性非常大。所以廣義來看,如果把彈性視為 100%,墨西哥為我們的供應鏈帶來了 85% 的彈性。另外 15% 則由愛爾蘭提供,而當巴西取得永久進口資格後也會補上——這會在 2019 年發生。
Lawrence Soren Keusch - MD
Lawrence Soren Keusch - MD
Great. And then Amy?
很好。那 Amy 呢?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Oh, and the second part about Amy. Well, I'm so happy she's joining the board. Amy was a colleague of mine at Covidien for many years and worked with me for 20-plus years at Covidien, so -- and Tyco Healthcare and Kendall Company. So we go back to 1995. She will be instrumental on the board in helping us not only M&A. Amy is a strategist, is a health care strategist. She's excellent in that area, and we're very excited that she will be part of helping us with strategy as well as making sure that our team is in the best shape ever. This is great news for Dennis Crowley, who you -- Dennis Crowley, who used to work for her for many, many years. And now she's on the board, so he has the benefit of her counsel again as she joins the board.
喔,至於 Amy 的第二部分。嗯,我非常高興她加入董事會。Amy 在 Covidien 多年來一直是我的同事,與我在 Covidien 共事 20 多年——也包括 Tyco Healthcare 和 Kendall Company。所以我們的淵源可以追溯到 1995 年。她在董事會上將扮演關鍵角色,不僅在併購(M&A)方面協助我們。Amy 是策略專家,是醫療保健策略專家。她在那個領域非常出色,我們也非常期待她能參與,協助我們制定策略,同時確保我們的團隊處於史上最佳狀態。這對 Dennis Crowley 來說也是好消息——你知道的——Dennis Crowley 過去很多很多年都在她麾下工作。而現在她加入董事會,他又能再次受益於她的建議與指導。
Operator
Operator
And our next question comes from Danielle Antalffy of Leerink.
下一個問題來自 Leerink 的 Danielle Antalffy。
Danielle Joy Antalffy - MD of Medical Supplies & Devices and Senior Analyst
Danielle Joy Antalffy - MD of Medical Supplies & Devices and Senior Analyst
Jay, I know how much you love to talk about cash flow. And not to nitpick on the quarter, but cash flow did come in a little bit under the updated guide, post Q3, for the year. Wondering if you could talk a little bit about that and what the drivers for the cash flow guidance for 2019 are.
Jay,我知道你很喜歡談現金流。我不是要吹毛求疵這一季,但今年的現金流確實比第三季之後更新的全年指引略低一些。想請你談談這點,以及 2019 年現金流指引的驅動因素是什麼。
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Certainly, Danielle. Thanks for the question. We -- as you know, I do always focus on cash flow. It's a critical number for us. From a fourth quarter perspective in 2018, actually -- it actually was quite a good quarter, right? Operating cash flow growth of 50% nearly and free cash flow growth essentially doubling. We grew $270 million to over $500 million. So very solid performance. But cash flow is admittedly a number that is very back-end loaded. A lot of the activity, roughly 40% of the cash flow in the year, comes in the fourth quarter, and a large component of that comes in December. And whenever you try to forecast performance in a month, there is a lot of choppiness to that. And so we -- to your point, we did come in a little bit below our expectations. The reality is there were a few factors in play. The sales mix came in a little bit different with more drugs and less devices. Some of the devices that we had earmarked to place in Q4 moved to Q1 with no implications to long-term revenues, solid customer demand. But like I say, difficult to anticipate exactly when devices will go out the door. And then the final factor, which is an interesting one, is some of our sales overperformance came in December. And whenever that happens, you get the inventory benefits to cash flow, but you don't get the payoff in the receivable collection. Even if you have a 30-day DSO, you're collecting -- if you make a sale in December, it's not going to show up until January.
當然,Danielle。謝謝你的提問。我們——如你所知,我一向都專注於現金流。這對我們來說是一個關鍵數字。從2018年第四季的角度來看,實際上——那確實是一個相當不錯的季度,對吧?營運現金流成長將近50%,自由現金流成長基本上翻倍。我們增加了2.7億美元,超過5億美元。所以表現非常穩健。但必須承認,現金流這個數字在年度分布上非常偏後段。一年中大約40%的現金流活動發生在第四季,而其中很大一部分發生在12月。而每當你試圖預測某一個月的表現時,波動就會很大。因此——如你所說,我們確實略低於我們的預期。實際上有幾個因素同時在起作用。銷售組合略有不同,藥品較多、器材較少。我們原本預計在第四季出貨的一些器材延後到第一季,對長期營收沒有影響,客戶需求依然強勁。但如我所說,很難精準預判器材究竟何時會出貨。最後一個因素也很有意思:我們部分超預期的銷售發生在12月。每當這種情況發生,你會在現金流上得到庫存方面的好處,但應收帳款回收的效益不會立刻反映。即使你的DSO是30天——如果你在12月完成銷售,回款也要到1月才會顯現。
And so you put all these factors in play, and cash flows did come in a little bit below our expectations. But I'll tell you, anytime we grow free cash flow 16%, 17%, which is basically what it was for the year, largely in line with earnings growth, I think it's a decent performance. And so as we look forward, we'll have a -- we have solid line of sight. Well, I hope that we have made some improvements to our process to get a better handle on December, but we use the word approximate when we talk about cash flow guidance for this very reason. I mean, it tends to be the most volatile number we forecast. But like I say, our conversion ratios are continuing to a very good extent. This continues to remain a focus for our entire organization. And in fact, later on today, Joe and I have a meeting with our supply chain team discussing our -- some improvements to our S&OP process. We brought in a new leader to this area, supply chain -- S&OP process is really the sales and operations planning process that we have at the company. So opportunity there, but, by and large, a very solid cash flow year.
因此把這些因素都放在一起看,現金流確實略低於我們的預期。但我想說,只要我們的年度自由現金流成長16%、17%——基本上就是今年的水準——而且大致與盈餘成長一致,我認為這是相當不錯的表現。所以展望未來,我們會有——我們有相當清晰的能見度。我也希望我們已經在流程上做了一些改善,以便更好掌握12月的情況;但正因如此,我們在談現金流指引時會用「約略」這個詞。我的意思是,這往往是我們預測中波動最大的一個數字。但如我所說,我們的轉換比率在很大程度上仍維持得非常好。這仍然是我們整個組織的重點。事實上,今天稍晚Joe和我會與供應鏈團隊開會,討論我們——對S&OP流程的一些改善。我們在這個領域引進了一位新的主管;供應鏈——S&OP流程其實就是公司內部的銷售與營運規劃流程。所以這裡有改善空間,但總體而言,這是一個非常穩健的現金流年度。
Operator
Operator
And our final question comes from the line of Matt Miksic of Credit Suisse.
我們最後一個問題來自Credit Suisse的Matt Miksic。
Matthew Stephan Miksic - Senior Research Analyst
Matthew Stephan Miksic - Senior Research Analyst
So a couple of clarifications here just on guidance and one on capital deployment. So maybe for Jay, just a clarification on Q1. The color on the 230 basis points of nonrecurring growth items in that 1% to 2% growth guidance was extremely helpful. If I look at that right, I just want to make sure we're looking at this the right way, this would sort of growth -- underlying growth, if you will, closer to 3.5% to 4.5% for the first quarter ex those items. And I'm just wondering, if that's true, just maybe flesh out the impact on the bottom line. I get about $0.05 to $0.07, but anything you could do to quantify that or color around that would be helpful. And then, as I say, one question on capital deployment.
我這裡有幾點釐清:兩點關於指引,一點關於資本配置。所以也許先請Jay釐清一下第一季。你對1%到2%成長指引中、那230個基點的非經常性成長項目的說明非常有幫助。如果我理解正確,我只是想確認我們看法一致:扣除那些項目後,第一季的成長——也就是所謂的基礎成長——會更接近3.5%到4.5%。如果是這樣,我想請你再多談談對損益表底線的影響。我估算大約是0.05到0.07美元,但如果你能量化或提供一些補充說明會很有幫助。然後,如我所說,還有一個關於資本配置的問題。
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Certainly. So in the first quarter, you're right, Matt, BREVIBLOC is $35 million. It's like 1.3%. The IV buy-in and in-center HD are another 2 factors, adding about 1%. So it is a fairly substantial impact. I'll stop short of adding those to the reported operational growth number to come up with this fictitious adjusted number. I don't want to do that. But you can certainly do that to get a more accurate long-term representation of what the growth rate will be. We try to be judicious at using adjusted financial measures here.
當然。所以在第一季,你說得對,Matt,BREVIBLOC是3,500萬美元。大約是1.3%。IV buy-in以及院內HD(in-center HD)是另外兩個因素,合計增加約1%。所以影響確實相當顯著。我不打算把這些加回到已揭露的營運成長數字,去得出一個虛構的調整後數字。我不想那樣做。但你當然可以這樣計算,以更準確地呈現長期的成長率會是什麼樣子。我們在使用調整後財務衡量指標方面會盡量審慎。
But then, from an EPS headwind standpoint, it's actually more than that because BREVIBLOC is a $0.05 headwind. Cyclo is a $0.01 headwind. Now that's not included in the operational sales growth number, but it is, of course, included in the EPS number. So that's a $0.01 headwind. And then foreign exchange is also a $0.03 headwind.
不過,從EPS逆風的角度來看,實際上影響比那更大,因為BREVIBLOC帶來0.05美元的逆風。Cyclo帶來0.01美元的逆風。這不包含在營運銷售成長數字裡,但當然包含在EPS數字中。所以那是0.01美元的逆風。另外,外匯也是0.03美元的逆風。
Now we have a number of good guys, things like share count and so on. But like I say, those are $0.09 of specific headwinds to the first quarter that, by and large, are the most pronounced in the first quarter of the year. And so you point to we do have a bit of a decline in EPS in the first quarter before we see the acceleration. But really, those are the key factors that impact that. I would say that the IV buy-in is also probably about $0.01 of impact to earnings with the in-center HD is less than that because it is a low-margin business. So that's really the overview.
同時我們也有一些正面因素,例如股數等。但如我所說,第一季有0.09美元的特定逆風,而且大致上在年度第一季最為明顯。因此你指出第一季EPS會有些下滑,之後才會看到加速。但真正影響的關鍵因素就是這些。我會說IV buy-in對盈餘的影響大概也約0.01美元,而院內HD(in-center HD)則低於此,因為那是低毛利業務。所以整體概況就是這樣。
Matthew Stephan Miksic - Senior Research Analyst
Matthew Stephan Miksic - Senior Research Analyst
Okay. No, that's super helpful. And on the follow-up, I guess taking kind of a similar analysis to the full year. And I understand your organic growth guidance is your organic growth guidance of 3% to 4%. But if we look at the 130 basis points kind of in a similar way, one could argue sort of the underlying growth of your businesses is already kind of tracking into that 4% to 5% long-term growth CAGR that you've talked about through 2020 at least. And that's our analysis, of course. But on the strategic front, I just want to confirm and clarify the thoughts on urgency for a deal. I think there's a perception that a deal is maybe more urgent somehow to get to this 4% to 5% growth and -- or whether potential enhancements to the portfolio and growth and so on, strategic investments would be additive to those long-term goals. Just any sort of clarifying thoughts you have on that as we wrap up the call.
好的。不,這非常有幫助。至於追問,我想用類似的分析方式看全年。我理解你們的有機成長指引就是3%到4%的有機成長指引。但如果用類似方式看那130個基點,有人可能會認為你們業務的基礎成長其實已經在追蹤你們談到至少到2020年的4%到5%長期成長CAGR。當然這是我們的分析。但在策略面,我想確認並釐清你們對交易急迫性的看法。市場上似乎有一種觀感:為了達到4%到5%的成長,某種交易可能更迫切——或者說,投資組合的潛在強化、成長等策略性投資,是否只是對那些長期目標的加分。在我們結束這通電話前,想請你就此提供任何釐清性的看法。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Matt -- no Mike. Sorry for that, Matt. I know you're Matt and now I've called you Mike. Matt, first of all, the worst thing that any of us can do here at Baxter is to rush into a deal just make sure that it helps us in the short term. And usually, those decisions are bad and ill-conceived ones. We are looking for deals for a while. That's why we have a strong M&A team on board. But that doesn't mean that we are desperate for a deal. We're not. As a matter of fact, we've turned many deals down. And I can tell you we may -- we did this in the last 3 quarters. We turned deals down because financials were not there. We couldn't make ends meet when we -- but we continue to explore every opportunity. We work very closely with our board in terms of creating a strategic intent, a strategic drive to bring the deals onboard. It has to be strategic. It has to be accretive. It has to return financially. It has to be a company that will benefit Baxter in the long term. So if we don't find it, we use the money for something else and benefit the bottom line of the company like we did at the end of '18. But there's no urgency. I want our investors to know that this thing of having to make a deal to make '19 happen or '20 happen, it will help us get even better, but it doesn't mean that we need them. And we will not make stupid decisions to get to the -- to a number just because we have the cash. Thank you.
Matt——不,是 Mike。Matt,抱歉。我知道你是 Matt,結果我剛剛叫你 Mike。Matt,首先,我們在 Baxter 這裡任何人能做的最糟糕的事情,就是為了確保短期內對我們有幫助而倉促達成一筆交易。而通常,那些決策都是不佳且欠周全的。我們一直在尋找交易機會。這也是為什麼我們有一支強大的併購(M&A)團隊。但這不代表我們急著要做交易。我們並不急。事實上,我們拒絕了很多交易。我可以告訴你,我們可能——我們在過去 3 個季度就是這麼做的。我們拒絕交易,是因為財務條件不符合。我們無法在我們——但我們仍會持續探索每一個機會。在制定策略意圖、以策略驅動把交易納入方面,我們與董事會密切合作。它必須具備策略性。它必須具增益性(accretive)。它必須在財務上帶來回報。它必須是一家能在長期讓 Baxter 受益的公司。所以如果我們找不到,我們就把資金用在其他事情上,並像 2018 年底那樣讓公司的盈餘表現受益。但沒有急迫性。我希望投資人知道,所謂一定要做一筆交易才能讓 2019 或 2020 成立這件事——它會幫助我們變得更好,但不代表我們非它不可。而且我們不會因為手上有現金,就為了達到——為了達到某個數字而做出愚蠢的決策。謝謝。
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Thanks, folks.
謝謝各位。
Operator
Operator
Thank you. And that concludes our question-and-answer session for today. Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day.
謝謝。以上就是我們今天的問答環節。各位女士、先生,感謝各位參與今天的電話會議。本次會議到此結束。各位可以掛線。祝大家今天愉快。